Since NI-0801 was expected to inhibit CXCL10-induced infiltration of inflammatory lymphocytes in the vicinity of bile ducts in PBC, the phase 2a study of NI-0801 was conducted. Here, CXCL10 is linked to primary biliary cholangitis.